Luis-Gerardo Rodriguez-Lobato
Overview
Explore the profile of Luis-Gerardo Rodriguez-Lobato including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lozano E, Mena M, Garrabou G, Cardus O, Diaz T, Moreno D, et al.
Clin Cancer Res
. 2024 Jul;
30(17):3944-3955.
PMID: 38990101
Purpose: TIGIT blockade in our ex vivo model of bone marrow (BM) reduced the number of malignant plasma cells (PC) in only half of patients with multiple myeloma. Here, we...
2.
Bruno B, Wasch R, Engelhardt M, Gay F, Giaccone L, DAgostino M, et al.
Haematologica
. 2021 Apr;
106(8):2054-2065.
PMID: 33792221
Chimeric antigen receptor (CAR) T cells (CAR-T) have dramatically changed the treatment landscape of B-cell malignancies, providing a potential cure for relapsed/refractory patients. Long-term responses in patients with acute lymphoblastic...
3.
Rodriguez-Lobato L, Martinez-Roca A, Castano-Diez S, Palomino-Mosquera A, Gutierrez-Garcia G, Pedraza A, et al.
PLoS One
. 2020 Nov;
15(11):e0241778.
PMID: 33147257
Background: Autologous stem cell transplantation (ASCT) remains the standard of care for young multiple myeloma (MM) patients; indeed, at-home ASCT has been positioned as an appropriate therapeutic strategy. However, despite...
4.
Lozano E, Mena M, Diaz T, Martin-Antonio B, Leon S, Rodriguez-Lobato L, et al.
Clin Cancer Res
. 2020 Jun;
26(17):4688-4698.
PMID: 32513837
Purpose: T-cell immunoreceptor with Ig and ITIM domain (TIGIT) blockade could represent an alternative therapeutic option to release the immune response in patients with multiple myeloma. Here we analyzed the...
5.
Lozano E, Diaz T, Mena M, Sune G, Calvo X, Calderon M, et al.
J Immunol
. 2018 Mar;
200(8):2581-2591.
PMID: 29531171
Mechanisms of immune regulation may control proliferation of aberrant plasma cells (PCs) in patients with monoclonal gammopathy of undetermined significance (MGUS) preventing progression to active multiple myeloma (MM). We hypothesized...
6.
Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression
Fernandez de Larrea C, Isola I, Pereira A, Cibeira M, Magnano L, Tovar N, et al.
Leukemia
. 2018 Feb;
32(6):1427-1434.
PMID: 29463830
Smoldering multiple myeloma (SMM) is a biologically heterogeneous, clinically defined entity with a variable rate of progression to symptomatic multiple myeloma (MM). Reliable markers for progression are critical for the...